Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
Nephrology Dialysis Transplantation · 04.05.2023 · 38 (5) · 1282-1296
DOI: 10.1093/ndt/gfac271 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 15.09.2022. Verfasst von Ursula Thiem und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III - Nephrology, Hypertension, Transplantation Medicine, Rheumatology, Geriatrics, Ordensklinikum Linz - Elisabethinen Hospit…. Hauptthemen laut MEDLINE: Renal Dialysis, Vascular Calcification. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vifor Pharma, Fresenius Medical Care, Medical Society of Upper Austria.
Abstract (Originalsprache)
Background
Calciprotein particles (CPPs), colloidal mineral-protein nanoparticles, have emerged as potential mediators of phosphate toxicity in dialysis patients, with putative links to vascular calcification, endothelial dysfunction and inflammation. We hypothesized that phosphate binder therapy with sucroferric oxyhydroxide (SO) would reduce endogenous CPP levels and attenuate pro-calcific and pro-inflammatory effects of patient serum towards human vascular cells in vitro.
Methods
This secondary analysis of a randomised controlled crossover study compared the effect of 2-week phosphate binder washout with high-dose (2000 mg/day) and low-dose (250 mg/day) SO therapy in 28 haemodialysis patients on serum CPP levels, inflammatory cytokine/chemokine arrays and human aortic smooth muscle cell (HASMC) and coronary artery endothelial cell (HCAEC) bioassays.
Results
In our cohort (75% male, 62 ± 12 years) high-dose SO reduced primary (amorphous) and secondary (crystalline) CPP levels {−62% [95% confidence interval (CI) −76 to −44], P < .0001 and −38% [−62 to −0.14], P < .001, respectively} compared with washout. Nine of 14 plasma cytokines/chemokines significantly decreased with high-dose SO, with consistent reductions in interleukin-6 (IL-6) and IL-8. Exposure of HASMC and HCAEC cultures to serum of SO-treated patients reduced calcification and markers of activation (IL-6, IL-8 and vascular cell adhesion protein 1) compared with washout. Serum-induced HASMC calcification and HCAEC activation was ameliorated by removal of the CPP-containing fraction from patient sera. Effects of CPP removal were confirmed in an independent cohort of chronic kidney disease patients.
Conclusions
High-dose SO reduced endogenous CPP formation in dialysis patients and yielded serum with attenuated pro-calcific and inflammatory effects in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine III - Nephrology, Hypertension, Transplantation Medicine, Rheumatology, Geriatrics, Ordensklinikum Linz - Elisabethinen Hospital, Linz, Austria.
- Johannes Kepler University Linz, Medical Faculty, Linz, Austria.
- Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
- Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
- CeMSIIS - Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University Vienna, Vienna, Austria.
- Calciscon AG, Nidau, Switzerland.
Förderung
- Vifor Pharma
- Fresenius Medical Care
- Medical Society of Upper Austria
- Viertel Charitable Foundation
- Royal Melbourne Hospital
Zitieren
APA
Thiem, U., Hewitson, T. D., Toussaint, N. D., Holt, S. G., Haller, M. C., Pasch, A., Cejka, D., & Smith, E. R. (2023). Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells. Nephrology Dialysis Transplantation, 38(5), 1282-1296. https://doi.org/10.1093/ndt/gfac271
Vancouver
Thiem U, Hewitson TD, Toussaint ND, Holt SG, Haller MC, Pasch A, et al. Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells. Nephrology Dialysis Transplantation. 2023;38(5):1282-1296. doi:10.1093/ndt/gfac271
BibTeX
@article{Thiem2023,
author = {Thiem, Ursula and Hewitson, Tim D and Toussaint, Nigel D and Holt, Stephen G and Haller, Maria C and Pasch, Andreas and Cejka, Daniel and Smith, Edward R},
title = {Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
volume = {38},
number = {5},
pages = {1282--1296},
doi = {10.1093/ndt/gfac271}
}
EUVIMED